Alzpedia
BACE1
Synonyms: beta-secretase 1, beta-Site amyloid beta A4 precursor protein-cleaving enzyme, memapsin-2 (membrane-associated aspartic protease 2), aspartyl protease 2 (ASP2), HSPC104
Quick Links
BACE1 encodes a transmembrane aspartyl protease responsible for β-secretase processing of the amyloid precursor protein (APP). APP cleavage by BACE1 is the rate-limiting step in the generation of Aβ peptides, creating the C99 fragment that becomes a substrate for subsequent γ-secretase cleavage. BACE1 is active in the acidic environment of early endosomes and trans-Golgi compartments, where Aβ is generated.
Its role in Aβ generation has made BACE1 a target for therapy development, and rational drug design efforts accelerated when the crystal structure of BACE was solved. A handful of BACE inhibitors have come to clinical trial, though some failed in Phase 1 due to safety concerns. BACE inhibitors are being watched for potential off-target effects of BACE1 inhibition, as the protease cleaves several dozen substrates. The best-studied is the cell surface protein neuregulin 1, whose soluble cleavage product signals through the receptor Erb4 on glial cells to regulate myelination. In addition, BACE1 is known to play a role in neurite outgrowth and muscle spindle formation. BACE knockout mice have mild schizophrenia-like and cognitive phenotypes.
The physiological function of APP processing by BACE1 remains unclear. The homolog BACE2 differs from BACE1 in its expression pattern and substrate specificity, and appears not to contribute significantly to Aβ generation.
References
Other Citations
Further Reading
News
- BACE—Substrates, Functions, Developmental Phenotypes
- Meeting Explores Complex Biology of BACE Regulation
- Paper Alert: BACE1 Required for Muscle Spindle, Motor Control
- Lilly Halts Phase 2 Trial of BACE Inhibitor Due to Liver Toxicity
- Paracrine Signal From BACE1-Clipped Neuregulin Rescues Myelin
- BACE Inhibitors Barrel Forward—Next Hurdles: Safety, Efficacy
- Rounding Second BACE: Another Route to Memory Loss?
- Wave of New BACE Inhibitors Heading to Phase 2
- BACE Secrets: Newly Identified Substrates May Regulate Plasticity
- Not the Usual Suspects: Tracking BACE Inhibition, Axon Role
- Q&A With Merck’s Johan Luthman
- Smuggling Antibodies to BACE Across the Blood-Brain Barrier
- Barcelona: Out of Left Field—Hit to The Eye Kills BACE Inhibitor
- Keystone: BACE, Age, Stress, Energy—Is Translation to Blame?
- BACE Regulates Sodium Channels, Neuronal Excitability
- Madrid: BACE News Roundup, Part 1
Papers
- Dislich B, Lichtenthaler SF. The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond. Front Physiol. 2012;3:8. PubMed.
- Tan J, Evin G. β-Site APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis. J Neurochem. 2012 Mar;120(6):869-80. PubMed.
- Kandalepas PC, Vassar R. Identification and biology of β-secretase. J Neurochem. 2012 Jan;120 Suppl 1:55-61. PubMed.
- Sun X, Bromley-Brits K, Song W. Regulation of β-site APP-cleaving enzyme 1 gene expression and its role in Alzheimer's disease. J Neurochem. 2012 Jan;120 Suppl 1:62-70. PubMed.
- Decourt B, Sabbagh MN. BACE1 as a potential biomarker for Alzheimer's disease. J Alzheimers Dis. 2011;24 Suppl 2:53-9. PubMed.
- Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009 Oct 14;29(41):12787-94. PubMed.